Call for breast cancer drug price reduction

April 23, 2014 1:15 pm

Campaigners are calling on pharmaceutical company Roche to cut the price of a pioneering new breast cancer treatment amid indications the NHS drugs watchdog is set to reject its use on the service on cost grounds. NICE said the £90,000 cost of trastuzumab emtansine is not justifiable. Sir Andrew Dillon, NICE Chief Executive, said: “We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS.”

Yahoo News.

If you would like to receive information and analysis on policy developments across our specialist sectors, please complete the following, indicating what sectors you would like to receive information on:







Contact us

We would be delighted to hear from you. If you would like to get in touch with us, please contact us on 020 7463 0690 or use the form below.

We look forward to hearing from you.

For media enquiries, please contact Mayar Raouf on 020 7463 0698 / 0750 232 7092, or email Mayar.Raouf@whitehouseconsulting.co.uk.

Contact us via email
  • ace centre
  • Pancreatic Cancer UK
  • Pancreatic Cancer UK
  • Team GB
  • Lilian Baylis Technology School

Sign up for the latest news

  • * Denotes required fields
  • This field is for validation purposes and should be left unchanged.

Contact us

  • * Denotes Required fields
  • This field is for validation purposes and should be left unchanged.